PF 04217903

Known as: MET Tyrosine Kinase Inhibitor PF-04217903, PF-04217903, PF04217903 
An orally bioavailabe, small-molecule tyrosine kinase inhibitor with potential antineoplastic activity. MET tyrosine kinase inhibitor PF-04217903… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2009-2017
02420092017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Oncogenic gene fusions have been identified in many cancers and many serve as biomarkers or targets for therapy. Here we identify… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2013
2013
Epithelial ovarian cancer (EOC) metastasizes transcoelomically to the peritoneum and omentum, and despite surgery and… (More)
Is this relevant?
2013
2013
Inhibition of VEGF signaling can promote lymph node metastasis in preclinical models, but the mechanism is not fully understood… (More)
Is this relevant?
2012
2012
The c-Met pathway has been implicated in a variety of human cancers for its critical role in tumor growth, invasion, and… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2012
Highly Cited
2012
UNLABELLED Invasion and metastasis increase after the inhibition of VEGF signaling in some preclinical tumor models. In the… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2012
2012
Targeting cancers with amplified or abnormally activated c-Met (hepatocyte growth factor receptor) may have therapeutic benefit… (More)
Is this relevant?
2012
2012
Targeting cancers with amplified or abnormally activated c-Met (hepatocyte growth factor receptor) may have therapeutic benefit… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2012
2012
The c-MET receptor tyrosine kinase is an attractive oncology target because of its critical role in human oncogenesis and tumor… (More)
Is this relevant?
2011
2011
The objective of this study was to assess the physiologically based pharmacokinetic (PBPK) model for predicting plasma… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2009
2009
The c-Met receptor tyrosine kinase (RTK) is a key regulator in cancer, in part, through oncogenic mutations. Eight clinically… (More)
Is this relevant?